Abstract:Cervical cancer is the third most commonly diagnosed cancer worldwide and the fourth leading cause of cancer-related mortality in females worldwide, accounting for 10-15% of cancer-related mortalities. Cytological screening and DNA testing for high-risk human papillomavirus (HPV) types have markedly decreased the rates of cervical cancer in developed countries, however, for vulnerable populations without access to health care, cervical cancer remains a considerable problem. Chemotherapeutic agents such as cisplatin (DDP) are considered as first-line treatment for cervical carcinoma. Although initially patients often exhibit high responsiveness, the majority eventually develop DDP resistance. However, the mechanisms underlying this process remain unclear. Furthermore, patients with metastatic cancer and those exhibiting persistent or recurrent disease after platinum-based chemoradiotherapy have limited options and thus, non-platinum combination chemotherapy has been proposed as a strategy to circumvent platinum resistance, however, novel therapeutic strategies are required. In the present study, P16 expression was analyzed by quantitative-polymerase chain reaction and western blot analysis in SiHa and SiHa-DDP cells and the interaction between P16 and CDK4 was detected via co-immunoprecipitation. In addition, the proliferation and apoptosis rates of P16 knockdown SiHa-DDP cells were measured by MTT assay and Annexin V flow cytometry and the subsequent changes in cyclin D1 and pRb expression were analyzed by western blot analysis. In this study, a high level of P16(INK4A) expression and its enhanced interaction with cyclin-dependent kinase-4 in cervical carcinoma DDP-resistance cells (SiHa-DDP) was identified, which was associated with the inactivation of phosphorylated retinoblastoma protein (pRb). Knockdown of P16(INK4A) significantly induced cellular growth, when compared with the control cells, via the upregulation of pRb, and also promoted apoptosis following treatment with DDP. The results of this study indicated, for the first time, that P16(INK4A) is required for DDP resistance in cervical carcinoma SiHa cells and, thus, these results may lead to the development of novel strategies for the treatment of chemoresistant cervical carcinoma.

Wild-Type P16(Ink4a) Suppresses Cell Growth, Telomerase Activity And Dna Repair In Human Breast Cancer Mcf-7 Cells

Inhibition of Breast Tumor Cell Growth by Ectopic Expression of P16/ink4a Via Combined Effects of Cell Cycle Arrest, Senescence and Apoptotic Induction, and Angiogenesis Inhibition

p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways

Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis

In Vitro Tumor Suppression of p16INK4a

P16 Promotes the Growth and Mobility Potential of Breast Cancer Both in Vitro and in Vivo: the Key Role of the Activation of IL-6/JAK2/STAT3 Signaling

Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition

p53 Deficiency leads to compensatory up-regulation of p16INK4a.

P16 Suppressor Gene and Tumor

P16 Reactivation Induces Anoikis and Exhibits Antitumour Potency by Downregulating Akt/survivin Signalling in Hepatocellular Carcinoma Cells.

Proliferative and Invasive Effects of Inhibitors of Kinase 4 (p15ink4b and P16ink4a/CDKN2) Gene Activation on RKO Human Colorectal Cancer Cells

P16 INK4A is required for cisplatin resistance in cervical carcinoma SiHa cells.

Relationship Between Expression And Methylation Status Of P16(Ink4a) And The Proliferative Activity Of Different Areas' Tumour Cells In Human Colorectal Cancer

Targeted P16(Ink4a) Epimutation Causes Tumorigenesis and Reduces Survival in Mice

C-terminal Binding Protein-2 Promotes Cell Proliferation and Migration in Breast Cancer Via Suppression of P16ink4a

OCT4B Regulates P53 and P16 Pathway Genes to Prevent Apoptosis of Breast Cancer Cells

P16ink4a Protein is a Specific Molecular Biomarker of Breast Cancer

Expression of p16INK4a in human malignant tumors and its clinical significance

Systemic transduction of p16INK4A antitumor peptide inhibits the growth of MBT-2 mouse bladder tumor cell line grafts.

Driving effect of P16 methylation on telomerase reverse transcriptase-mediated immortalization and transformation of normal human fibroblasts

Cell Senescence and Transcriptional Regulation of P16ink4a